New registry will generate robust real-world evidence on disease burden, treatment patterns and long-term effectiveness of newly approved and emerging therapies

 Thermo Fisher Scientific, the world leader in serving science, announced the launch of the PPD™ CorEvitas™ Chronic Hand Eczema Registry, a prospective, observational cohort registry designed to generate real-world evidence on patients being treated for chronic hand eczema in routine clinical care.

The new registry, which is open to enrollment in North America, will, like all CorEvitas Registries, feature primary collection of proprietary, prospectively collected clinical data to support evaluation of disease history, treatment patterns, comorbidities and the long-term effectiveness of newly approved and emerging therapies. 

“Chronic hand eczema can be difficult to manage because symptoms often persist due to occupational exposures, affecting patients’ day-to-day activities, work productivity and quality of life,” said Dr. Peter Wahl, vice president and global head of scientific affairs for PPD CorEvitas Clinical Registries. “A unique feature of this registry is collection of patient-reported symptoms, treatment experience and quality of life and work productivity at 7 days and 30 days post-drug initiation, capturing the patient's perspective on rapid response to a new treatment.”

Chronic hand eczema is a common inflammatory skin condition characterized by persistent hand dermatitis that lasts more than three months or recurs at least twice a year1. The condition is often multifactorial, involving genetic predisposition, environmental factors and triggers such as irritants and allergens1. It is also the most frequent occupational skin disease, particularly among workers exposed to “wet work,” including health care workers, food handlers and hairdressers2.

Physician-diagnosed chronic hand eczema affects 9.6% of U.S. adults3, and the condition can interfere with daily activities and have a significant negative impact on quality of life and patients' ability to earn a living. 

CorEvitas Clinical Registries are proprietary multi-drug disease registries conducting primary data collection of disease activity and treatment outcome measures to support regulatory-grade evidence needs to drive regulator clinical stakeholder decision-making.